{
    "2018-10-02": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Health Care Stocks Gurus Are Buying",
                "features": {
                    "keywords": [
                        "health",
                        "care",
                        "stocks",
                        "gurus",
                        "buying"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Here's Why Antares Pharma Jumped Higher Today",
                "features": {
                    "keywords": [
                        "antares",
                        "pharma",
                        "jumped",
                        "higher"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Here's Why Antares Pharma Jumped Higher Today",
                "features": {
                    "keywords": [
                        "antares",
                        "pharma",
                        "jumped",
                        "higher"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Examining the Performances of Eli Lilly’s Oncology Products",
                "features": {
                    "keywords": [
                        "examining",
                        "performances",
                        "eli",
                        "lilly",
                        "oncology",
                        "products"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental",
                "features": {
                    "keywords": [
                        "zacks",
                        "analyst",
                        "blog",
                        "exxonmobil",
                        "disney",
                        "abbvie",
                        "bristol-myers",
                        "united",
                        "continental"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "energy",
                        "entertainment",
                        "pharmaceuticals",
                        "transportation"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "How Eli Lilly’s Cardiovascular Products Have Been Faring",
                "features": {
                    "keywords": [
                        "eli",
                        "lilly",
                        "cardiovascular",
                        "products",
                        "faring"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "cardiovascular"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-25",
                "original_text": "IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "features": {
                    "keywords": [
                        "important",
                        "deadline",
                        "reminder",
                        "schall",
                        "law",
                        "firm",
                        "class",
                        "action",
                        "lawsuit",
                        "abbvie",
                        "investors",
                        "losses"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}